3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Leukemia, Myeloid, Acute
3
Squamous Cell Carcinoma of Head and Neck
2
Myelodysplastic Syndromes
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Tongue Neoplasms
1
Thrombocythemia, Essential
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Nasopharyngeal Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Esophagitis
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
ESCC
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Nivolumab
5
pembrolizumab
3
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
durvalumab
2
atezolizumab
2
Celecoxib
2
spartalizumab
1
relatlimab
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
danvatirsen
1
XELOX
1
Surgical Procedures, Operative
1
Oxaliplatin
1
Leucovorin
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
IMM-101
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
DEAE-Dextran
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Turcot syndrome
×
Induction Chemotherapy
×
Clear all
NCT07259473
2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
15 enrolled